<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938522</url>
  </required_header>
  <id_info>
    <org_study_id>2009-06-031</org_study_id>
    <nct_id>NCT00938522</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention</brief_title>
  <acronym>PRECEDE</acronym>
  <official_title>PREtreatment of Cilostazol Loading in Elective Percutaneous Coronary Intervention to Decrease Adverse Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of cilostazol loading before planned
      PCI on major adverse cardiac and cerebrovascular events in patients with coronary artery
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCEs: composite of death, myocardial infarction, cerebrovascular event, and target vessel revascularization)</measure>
    <time_frame>at 3 months after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late loss on quantitative coronary angiography</measure>
    <time_frame>9 months after index PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% neointimal area [100 x (stent area-lumen area)/stent area] on IVUS</measure>
    <time_frame>9 months after index PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCEs: composite of death, myocardial infarction, cerebrovascular event, and target vessel revascularization)</measure>
    <time_frame>12 months after index PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>Cilostazol loading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.</description>
    <arm_group_label>Cilostazol loading</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective PCI

          -  Presence of coronary lesions amenable to stent

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Urgent PCI

          -  Hypersensitivity to aspirin, clopidogrel, or cilostazol

          -  LVEF &lt; 30% or congestive heart failure

          -  Bleeding diathesis

          -  leukocyte count &lt; 3,000/mm3 and/or platelet count &lt; 100,000/mm3

          -  aspartate aminotransferase or alanine aminotransferase &gt; 3 times upper normal; serum
             creatinine &gt; 2.0 mg/dl

          -  noncardiac disease with a life expectancy &lt; 1 year

          -  inability to follow the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
    <phone>82-2-3410-3418</phone>
    <email>hc.gwon@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Bin Song, MD, PhD</last_name>
    <phone>82-2-3410-1333</phone>
    <email>youngbin.song@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
      <phone>82-2-3410-3418</phone>
      <email>hc.gwon@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <last_update_submitted>July 20, 2009</last_update_submitted>
  <last_update_submitted_qc>July 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>HC Gwon, MD, PhD</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>Cilostazol loading</keyword>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

